Rheumatoid Arthritis News

The holidays for many people represent a time of indulgence in food and drink, but for patients with gout, these feasts can be veritable minefields that can trigger painful flares.

Osteoporosis remains highly prevalent among patients with rheumatoid arthritis despite advancements in prevention and treatment, according to data published in Scientific Reports.

In 2021, Humira, the blockbuster biologic that has for years been the highest grossing drug in the world, accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

PHILADELPHIA — When analyzing patients with rheumatoid arthritis based on their comorbidities, certain groups experienced differing survival outcomes when compared with the expected mortality of the general population.

PHILADELPHIA — Patients with rheumatoid arthritis who were treated with upadacitinib demonstrated improvement in pain, fatigue and morning stiffness from week 1 through week 12, according to data presented at ACR Convergence 2022.

The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.

PHILADELPHIA — Although most primary care physicians understand the importance for early diagnosis and management of rheumatoid arthritis, there is discomfort with making the initial diagnosis, a speaker said at ACR Convergence 2022.

Patients with rheumatic immune-mediated inflammatory disease who experience myocardial infarction are more likely to die or experience heart failure vs. patients without immune-mediated inflammatory disease, according to data.

PHILADELPHIA — Discordance with the treatment goals of providers among patients with rheumatoid arthritis was associated with age, gender, age at diagnosis and other factors of care, according to survey data presented at ACR Convergence 2022.

The FDA has accepted an abbreviated biologics license application for a tocilizumab biosimilar candidate, according to a press release from Biogen.